The Chronic Care Policy Alliance (CCPA) recently submitted letters to the Senate HELP and Finance Committees, as well as the House Ways and Means and Energy and Commerce Committees, opposing proposals to implement a Most Favored Nation (MFN) drug pricing model in the United States.
In the letters, CCPA raises concerns that MFN policies prioritize government savings over meaningful improvements in patient affordability and could undermine access to treatments for individuals with chronic and serious conditions, warning that tying U.S. drug prices to international benchmarks may import restrictive cost-effectiveness frameworks and limit timely access to innovative therapies.
CCPA urges Congress to reject MFN proposals and instead pursue patient-centered reforms that lower out-of-pocket costs, improve transparency, and ensure patients benefit directly from savings within the healthcare system.
Read our letter to the Senate HELP committee here.
Read our letter to the Senate Finance committee here.
Read our letter to the House Ways and Means committee here.
Read our letter to the House Energy and Commerce committee here.